Skip to Content
Merck
  • Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy (2011-11-23)
Thomas Grau, Petra Selchow, Marcel Tigges, Reto Burri, Marc Gitzinger, Erik C Böttger, Martin Fussenegger, Peter Sander
ABSTRACT

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethionamide
Sigma-Aldrich
N-Phenylthiourea, ≥98%